RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Shield Therapeutics Stock

Shield Therapeutics P/S 2024

Shield Therapeutics P/S

0.5

Ticker

STX.L

ISIN

GB00BYV81293

WKN

A2AE98

As of Oct 22, 2024, Shield Therapeutics's P/S ratio stood at 0.5, a -86.49% change from the 3.7 P/S ratio recorded in the previous year.

The Shield Therapeutics P/S history

Shield Therapeutics Aktienanalyse

What does Shield Therapeutics do?

The company Shield Therapeutics PLC is a renowned British pharmaceutical conglomerate, founded in 2008. Based in Gateshead, England, Shield Therapeutics specializes in the development and marketing of pharmaceutical products, with a particular focus on iron deficiency anemia. The company also has a strong presence in Europe and Asia. Shield Therapeutics' business model is to provide high-quality and innovative medical solutions to improve people's health and well-being. The company continuously researches new products to better cater to the needs of patients and doctors. The focus of Shield Therapeutics is on combating iron deficiency anemia, a severe blood disorder caused by a lack of iron in the body. Iron deficiency can be attributed to various factors, such as inadequate food intake, blood loss, or iron deficiency accumulation due to diseases. This anemia can lead to a range of symptoms, including fatigue, weak muscles, and dizziness. Long-term consequences can include life-threatening complications such as heart failure and strokes. Shield Therapeutics offers various products that can be used to treat iron deficiency anemia, such as Feraccru (in injection form) and Accrufer / Accrufer Tablets (in tablet form). Feraccru is an orally absorbed iron preparation indicated for the treatment of anemia in adults with iron deficiency anemia. Accrufer / Accrufer Tablets is an iron salt complex that is rapidly absorbed and shows high efficacy. The company also has its own research and development department, which focuses on researching innovative therapies and treatment methods. Shield Therapeutics actively participates in clinical research and the development of new therapeutic options aimed at improving the quality of life for people with iron deficiency anemia. More recently, Shield Therapeutics has also ventured into other disease areas. The company has developed clinical studies in collaboration with a top 10 pharmaceutical company to modify atherosclerosis through iron chelators. This is a groundbreaking research field that aims to develop advanced therapies for the treatment of infertility and chronic obstructive pulmonary disease (COPD). Overall, Shield Therapeutics has experienced strong growth in recent years and has solidified its position as a leading provider of pharmaceutical products for the treatment of iron deficiency anemia. The company has developed a wide range of products and can rely on a strong research and development department that constantly faces new challenges and offers innovative solutions for a variety of health issues. If Shield Therapeutics continues to be successful, it will undoubtedly continue to play a significant role in the industry. Answer: The company Shield Therapeutics specializes in the development and marketing of pharmaceutical products, with a particular focus on iron deficiency anemia. Shield Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Shield Therapeutics's P/S Ratio

Shield Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Shield Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Shield Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Shield Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Shield Therapeutics stock

What is the price-to-earnings ratio of Shield Therapeutics?

The price-earnings ratio of Shield Therapeutics is currently 0.5.

How has the price-earnings ratio of Shield Therapeutics changed compared to last year?

The price-to-earnings ratio of Shield Therapeutics has increased by -86.49% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Shield Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Shield Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Shield Therapeutics affect the company?

An increase in the price-earnings ratio of Shield Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Shield Therapeutics affect the company?

A decrease in the price-earnings ratio of Shield Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Shield Therapeutics?

Some factors that influence the price-earnings ratio of Shield Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Shield Therapeutics pay?

Over the past 12 months, Shield Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Shield Therapeutics is expected to pay a dividend of 0 GBP.

What is the dividend yield of Shield Therapeutics?

The current dividend yield of Shield Therapeutics is .

When does Shield Therapeutics pay dividends?

Shield Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Shield Therapeutics?

Shield Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Shield Therapeutics?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Shield Therapeutics located?

Shield Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shield Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shield Therapeutics from 10/22/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 10/22/2024.

When did Shield Therapeutics pay the last dividend?

The last dividend was paid out on 10/22/2024.

What was the dividend of Shield Therapeutics in the year 2023?

In the year 2023, Shield Therapeutics distributed 0 GBP as dividends.

In which currency does Shield Therapeutics pay out the dividend?

The dividends of Shield Therapeutics are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Shield Therapeutics

Our stock analysis for Shield Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shield Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.